Jivi

RSS

damoctocog alfa pegol

Authorised
This medicine is authorised for use in the European Union.

Overview

Jivi is a medicine used to treat and prevent bleeding in patients with haemophilia A, an inherited bleeding disorder caused by lack of a clotting protein called factor VIII. Jivi can be used in adults and children from 12 years of age who have been treated previously.

Jivi contains the active substance damoctocog alfa pegol.

This EPAR was last updated on 28/01/2019

Authorisation details

Product details
Name
Jivi
Agency product number
EMEA/H/C/004054
Active substance
Damoctocog alfa pegol
International non-proprietary name (INN) or common name
damoctocog alfa pegol
Therapeutic area (MeSH)
Hemophilia A
Anatomical therapeutic chemical (ATC) code
B02BD02
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Bayer AG
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
22/11/2018
Contact address

51368 Leverkusen
Germany

Product information

22/11/2018 Jivi - EMEA/H/C/004054 - -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antihemorrhagics

Therapeutic indication

Treatment and prophylaxis of bleeding in previously treated patients ≥ 12 years of age with haemophilia A (congenital factor VIII deficiency).

Assessment history

How useful was this page?

Add your rating